Pfizer strikes $1.2bn licensing deal for Biohaven migraine d...

Pfizer has bolstered its central nervous system (CNS) drugs portfolio with a $1.2 billion deal to claim rights outside the US to Biohaven's Nurtec ODT, an oral therapy for migraine.

AbbVie's Qulipta cleared for migraine prevention, setting up...

AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Qulipta – its once-daily oral preventive therapy for episodic migraines.

Bad news for Biohaven as verdiperstat flunks first phase 3 t...

Biohaven's key pipeline drug verdiperstat has failed to have any Therapeutic effect in patients with the rare neurological disorder multiple system atrophy (MSA) – its lead indication – but

Biohaven ALS drug blocked by FDA over manufacturing issue